Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
Open Access
- 26 November 2012
- journal article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 4 (6) , 50
Abstract
Introduction: A substantial number of therapeutic drugs for Alzheimer's disease (AD) have failed in late-stage trials, highlighting the translational disconnect with pathology-based animal models. Methods: To bridge the gap between preclinical animal models and clinical outcomes, we implemented a conductance-based computational model of cortical circuitry to simulate working memory as a measure for cognitive function. The model was initially calibrated using preclinical data on receptor pharmacology of catecholamine and cholinergic neurotransmitters. The pathology of AD was subsequently implemented as synaptic and neuronal loss and a decrease in cholinergic tone. The model was further calibrated with clinical Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) results on acetylcholinesterase inhibitors and 5-HT6 antagonists to improve the model's prediction of clinical outcomes. Results: As an independent validation, we reproduced clinical data for apolipoprotein E (APOE) genotypes showing that the ApoE4 genotype reduces the network performance much more in mild cognitive impairment conditions than at later stages of AD pathology. We then demonstrated the differential effect of memantine, an N-Methyl-D-aspartic acid (NMDA) subunit selective weak inhibitor, in early and late AD pathology, and show that inhibition of the NMDA receptor NR2C/NR2D subunits located on inhibitory interneurons compensates for the greater excitatory decline observed with pathology. Conclusions: This quantitative systems pharmacology approach is shown to be complementary to traditional animal models, with the potential to assess potential off-target effects, the consequences of pharmacologically active human metabolites, the effect of comedications, and the impact of a small number of well described genotypes.Keywords
This publication has 96 references indexed in Scilit:
- How Inhibition Shapes Cortical ActivityNeuron, 2011
- Multiple models to capture the variability in biological neurons and networksNature Neuroscience, 2011
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Memory efficiency and the strategic control of attention at encoding: Impairments of value-directed remembering in Alzheimer’s disease.Neuropsychology, 2009
- Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer’s Disease and Amyloid NeuroprotectionPharmacological Reviews, 2009
- Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersTrends in Pharmacological Sciences, 2009
- Dopamine modulates an mGluR5-mediated depolarization underlying prefrontal persistent activityNature Neuroscience, 2009
- Subcellular distribution of M2 muscarinic receptors in relation to dopaminergic neurons of the rat ventral tegmental areaJournal of Comparative Neurology, 2006
- Attractor dynamics in a modular network model of neocortexNetwork: Computation in Neural Systems, 2006
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993